ECP
CLVS

Elk Creek Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

Elk Creek Partners’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$4.74M Buy
745,486
+170,870
+30% +$1.37M 0.81% 57
2019
Q4 		$5.99M Sell
574,616
-2,498,934
-81% -$18.2M 0.69% 73
2019
Q3 		$12.1M Buy
3,073,550
+2,046,575
+199% +$16.6M 1.04% 32
2019
Q2 		$15.3M Buy
1,026,975
+525,251
+105% +$9.49M 1.14% 22
2019
Q1 		$12.5M Buy
501,724
+121,551
+32% +$3.05M 0.9% 38
2018
Q4 		$6.83M Buy
+380,173
New +$7.77M 0.57% 75

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Elk Creek Partners's CLVS Position: Q1 2020 in Review

Elk Creek Partners increased its Clovis Oncology, Inc. (CLVS) stake by 30% in Q1 2020, buying an estimated $1.37M and bringing the position to 745,486 shares worth $4.74M. The position accounts for 0.81% of the portfolio, ranked #57.

Elk Creek Partners first reported a position in CLVS in Q4 2018 and has held it in 6 quarters since. The position peaked at $15.3M in Q2 2019. 154 funds tracked by Wall St. Rank hold CLVS as of Q1 2020.

  • Elk Creek Partners held 745,486 shares of Clovis Oncology, Inc. worth $4.74M as of Q1 2020.
  • Elk Creek Partners bought 170,870 Clovis Oncology, Inc. shares in Q1 2020, an estimated $1.37M.
  • Clovis Oncology, Inc. made up 0.81% of Elk Creek Partners's portfolio in Q1 2020, its #57 holding.
  • Elk Creek Partners first reported a position in Clovis Oncology, Inc. in Q4 2018 and has held it in 6 quarters since.
  • Elk Creek Partners's Clovis Oncology, Inc. position peaked at $15.3M in Q2 2019.
  • 154 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2020.

Based on Elk Creek Partners's 13F filing for Q1 2020, filed 14 May 2020.